Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Characteristics and Outcomes of Acute Myeloid Leukemia in Ethnically Diverse Asians in Singapore

Natasha Fay Anthony, Yen-Lin Chee, Pak Ling Lui, Esther Chan, Michelle Poon, Lip Kun Tan, Jameelah Binte Sekh Mohamed, Liang Piu Koh, Melissa G OOI, Wee-Joo Chng, Wei-Ying Jen

Blood (2024) 144 (Supplement 1): 7899.

https://doi.org/10.1182/blood-2024-198845

Published: 2024

Journal Articles

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Blood (2024) 144 (Supplement 1): 213.

https://doi.org/10.1182/blood-2024-194827

Published: 2024

Journal Articles

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Blood (2024) 144 (Supplement 1): 353.

https://doi.org/10.1182/blood-2024-198326

Published: 2024

Journal Articles

Proliferative CD8 T-Cells: A Novel Immune Microenvironmental Determinant of Outcomes in Multiple Myeloma with Translocation (4;14)

Blood (2024) 144 (Supplement 1): 1950.

https://doi.org/10.1182/blood-2024-198769

Published: 2024

Journal Articles

Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis

Phaik Ju Teoh, Omer An, Tae-Hoon Chung, Jing Yuan Chooi, Sabrina H. M. Toh, Shuangyi Fan, Wilson Wang, Bryan T. H. Koh, Melissa J. Fullwood, Melissa G. Ooi, Sanjay de Mel, Cinnie Y. Soekojo, Leilei Chen, Siok Bian Ng, Henry Yang, Wee Joo Chng

Blood (2018) 132 (12): 1304–1317.

https://doi.org/10.1182/blood-2018-02-832576

Published: 2018

Includes: Supplemental data

Journal Articles

Cytogenetic Abnormalities and Treatment with New Drugs on Clinical Trials Are Important Prognostic Markers for Myeloma in the Era of ISS and FISH Analysis

Cinnie Yentia Soekojo, Adeline Lin, Michelle Poon, Liang Piu Koh, Lip Kun Tan, Melissa G. Ooi, Wee Joo Chng, MB ChB, MRCP, PhD

Blood (2016) 128 (22): 4498.

https://doi.org/10.1182/blood.V128.22.4498.4498

Published: 2016

Journal Articles

Paediatric-Inspired Acute Lymphoblastic Leukemia Protocols, Are They Too Toxic for Young Adults?

Melissa G. Ooi, MDMRCP FRCPath PhD, Wee J Chng, MD MRCP, FRCPATH, PhD, Chin-Hin Ng, MD MRCP, FRCPATH, Yi Ching Yuen, MClinPharm, BCOP, BCPS, CGP, Allen Eng Juh Yeoh, MD, Chiew Kean Hui, Elaine Seah, BSc

Blood (2016) 128 (22): 5162.

https://doi.org/10.1182/blood.V128.22.5162.5162

Published: 2016

Journal Articles

Bortezomib Based Induction Is Superior to Thalidomide Based Induction in Reducing Early Relapses Following Upfront HDM: an Analysis By the Asian Myeloma Working Group

Sathish Kumar Gopalakrishnan, FRCPath, Shin-Yeu Ong, MD MRCP, MSE, Seok Jin Kim, Hae Su Kim, MD, Ji Yun Lee, Sung Hee Lim, Yunxin Chen, MBBS, MRCP, FRCPath, Sanjay De Mel, BSc, FRCPath, MRCP,, Melissa G. Ooi, Shilpa Surendran, MBBS, Adeline Lin, Daryl Tan, MBBS, MRCP, Brian G M Durie, Wee Joo Chng, MB ChB, MRCP, PhD, Kihyun Kim, MD PhD

Blood (2016) 128 (22): 4650.

https://doi.org/10.1182/blood.V128.22.4650.4650

Published: 2016

Journal Articles

Vinorelbine-Cyclophosphamide Compared to Cyclophosphamide in Peripheral Blood Stem Cell Mobilization for Multiple Myeloma

Sanjay De Mel, BSc,FRCPath,MRCP,, Yunxin Chen, MBBS,MRCP,, Adeline Lin, BSc, Eng Soo Yap, MBBS, Teck Guan Soh, Joanna Mah, Melissa G. Ooi, Sathish Kumar Gopalakrishnan, Lara Kristina Sioco Donato, Nurul Aidah Abdul Halim, Wee-Joo Chng, MB, ChB, PhD, lip Kun Tan

Blood (2015) 126 (23): 3103.

https://doi.org/10.1182/blood.V126.23.3103.3103

Published: 2015

Journal Articles

The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias.

Melissa G Ooi, M.D., Robert O'Connor, Ph.D, Jana Jakubikova, Ph.D, Justine Meiller, Diploma, in, Biochemistry, Degre, Steffen Klippel, Ph.D, Jake Delmore, Efstathios Kastritis, M.D, Douglas McMillin, Ph.D, Martin Clynes, Ph.D, Paul Richardson, M.D., Constantine S. Mitsiades, M.D., Ph.D, Peter O'Gorman, M.D., Kenneth C. Anderson, M.D.

Blood (2009) 114 (22): 1729.

https://doi.org/10.1182/blood.V114.22.1729.1729

Published: 2009

Journal Articles

Methyljasmonate, An Inhibitor of Glycolytic Energy Production, Displays Pre-Clinical Activity against Multiple Myeloma Cells.

Steffen Klippel, Jana Jakubikova, Jake Delmore, Melissa G. Ooi, Douglas McMillin, Efstathios Kastritis, Jacob Laubach, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2009) 114 (22): 1741.

https://doi.org/10.1182/blood.V114.22.1741.1741

Published: 2009

Journal Articles

Proteomics as a Functional Tool in Evaluating Bortezomib Treatment and Drug Resistance Mechanism.

Melissa G Ooi, M.D., Paul Dowling, Ph.D, Paul Richardson, M.D., Constantine S. Mitsiades, M.D., Ph.D, Martin Clynes, Ph.D, Kenneth C. Anderson, Peter O'Gorman, M.D.

Blood (2009) 114 (22): 1805.

https://doi.org/10.1182/blood.V114.22.1805.1805

Published: 2009

Journal Articles

The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies.

Jake Delmore, David N. Cervi, Douglas McMillin, Efstathios Kastritis, Jana Jakubikova, Melissa G. Ooi, Steffen Klippel, Joseph M. Negri, Leutz Buon, Jacob Laubach, Luca Rastelli, Ann Clark, Samantha M. Sarno, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades, M.D., Ph.D

Blood (2009) 114 (22): 730.

https://doi.org/10.1182/blood.V114.22.730.730

Published: 2009

Journal Articles

Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications.

Jana Jakubikova, David N. Cervi, John F. Daley, Danka Cholujova, Melissa G. Ooi, Steffen Klippel, Simona Blotta, Merav Leiba, Jake Delmore, Douglas McMillin, Efstathios Kastritis, Jacob Laubach, Paul Richardson, Jan Sedlak, Kenneth C. Anderson, Constantine S. Mitsiades, M.D., Ph.D

Blood (2009) 114 (22): 954.

https://doi.org/10.1182/blood.V114.22.954.954

Published: 2009

Journal Articles

Activity of Plk Inhibitor BI2536 on Myeloma Cells

Douglas W. McMillin, PhD, Joseph Negri, Jake Delmore, Melissa G. Ooi, MD, Jana Jakubikova, Renee Wright, Nathanael Gray, PhD, Andrew Kung, MD, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD

Blood (2008) 112 (11): 2764.

https://doi.org/10.1182/blood.V112.11.2764.2764

Published: 2008

Journal Articles

Interactions of the Mdm2/p53 and Proteasome Pathways: Implications for Combination Strategies to Enhance the Anti-Myeloma Activity of Bortezomib

Melissa G. Ooi, Patrick J. Hayden, Douglas W. McMillin, Joseph M. Negri, Jake Delmore, Noopur S Raje, Nikhil C. Munshi, Dharminder Chauhan, Teru Hideshima, Paul G. Richardson, Constantine S. Mitsiades, Kenneth C Anderson, Nicholas Mitsiades

Blood (2008) 112 (11): 2651.

https://doi.org/10.1182/blood.V112.11.2651.2651

Published: 2008

Journal Articles

The Antidiabetic Biguanide Metformin Induces Growth Arrest in Multiple Myeloma Cells in Vitro, overcoming the Effect of Stromal Cells

Melissa G. Ooi, Douglas W. McMillin, Joseph M. Negri, Jake Delmore, Nikhil C. Munshi, Dharminder Chauhan, Teru Hideshima, Paul G. Richardson, Constantine S. Mitsiades, Kenneth C. Anderson, Nicholas Mitsiades

Blood (2008) 112 (11): 2652.

https://doi.org/10.1182/blood.V112.11.2652.2652

Published: 2008

Journal Articles

Synergistic Activity of Adenosine A2A and Beta-2 Adrenergic Receptor Agonists in Myeloma Cells in the Context of Tumor-Stromal Interactions

Douglas W. McMillin, PhD, Richard Rickles, Joseph Negri, Jake Delmore, Melissa G. Ooi, MD, Melissa Farwell, David Crowe, Mei Chen, William Avery, Vikram Kansra, PhD, Kenneth C. Anderson, MD, Margaret S. Lee, PhD, Constantine S. Mitsiades, MD, PhD

Blood (2008) 112 (11): 2663.

https://doi.org/10.1182/blood.V112.11.2663.2663

Published: 2008

Journal Articles

Compartment-Specific Bioluminescence Imaging (CS-BLI) High- Throughput Assays Provide Comparative Insights into the Impact of Osteoclasts Vs. Stromal Cells on Activity of Anti-Myeloma Therapeutics

Melissa G. Ooi, Douglas W. McMillin, Joseph M. Negri, Jake Delmore, Steffen Klippel, Nicholas Mitsiades, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2008) 112 (11): 219.

https://doi.org/10.1182/blood.V112.11.219.219

Published: 2008

NARROW

Characteristics and Outcomes of Acute Myeloid Leukemia in Ethnically Diverse Asians in Singapore

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Proliferative CD8 T-Cells: A Novel Immune Microenvironmental Determinant of Outcomes in Multiple Myeloma with Translocation (4;14)

Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis

Cytogenetic Abnormalities and Treatment with New Drugs on Clinical Trials Are Important Prognostic Markers for Myeloma in the Era of ISS and FISH Analysis

Paediatric-Inspired Acute Lymphoblastic Leukemia Protocols, Are They Too Toxic for Young Adults?

Bortezomib Based Induction Is Superior to Thalidomide Based Induction in Reducing Early Relapses Following Upfront HDM: an Analysis By the Asian Myeloma Working Group

Vinorelbine-Cyclophosphamide Compared to Cyclophosphamide in Peripheral Blood Stem Cell Mobilization for Multiple Myeloma

The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias.

Methyljasmonate, An Inhibitor of Glycolytic Energy Production, Displays Pre-Clinical Activity against Multiple Myeloma Cells.

Proteomics as a Functional Tool in Evaluating Bortezomib Treatment and Drug Resistance Mechanism.

The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies.

Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications.

Activity of Plk Inhibitor BI2536 on Myeloma Cells

Interactions of the Mdm2/p53 and Proteasome Pathways: Implications for Combination Strategies to Enhance the Anti-Myeloma Activity of Bortezomib

The Antidiabetic Biguanide Metformin Induces Growth Arrest in Multiple Myeloma Cells in Vitro, overcoming the Effect of Stromal Cells

Synergistic Activity of Adenosine A2A and Beta-2 Adrenergic Receptor Agonists in Myeloma Cells in the Context of Tumor-Stromal Interactions

Compartment-Specific Bioluminescence Imaging (CS-BLI) High- Throughput Assays Provide Comparative Insights into the Impact of Osteoclasts Vs. Stromal Cells on Activity of Anti-Myeloma Therapeutics

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only